Targovax’s ONCOS-102 receives FDA fast track designation for malignant pleural mesothelioma treatment

In a significant development for cancer treatment, Targovax, a Norwegian biotech firm specializing in immune-oncology, has announced that its lead candidate, ONCOS-102, has been granted ... Read More